Actively Recruiting
Evaluating Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 Given at Birth in Healthy Infants Vaccinated with IPV
Led by Fidec Corporation · Updated on 2026-09-09
740
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of a new type 2 oral poliovirus vaccine nOPV2 given at birth on healthy infants who have also received three doses of inactivated poliovirus vaccine IPV at 6, 10, and 14 weeks. The goal is to compare the levels of poliovirus type-2 found in stool samples at the time of an nOPV2 challenge and during follow-up across three groups of newborns. This phase 3 trial addresses public health concerns about circulating vaccine-derived poliovirus type 2 outbreaks by evaluating the transmissibility of the virus after vaccination. Participants are divided into three groups one group receives one dose of nOPV2 at birth plus the IPV schedule, another group receives two doses of nOPV2 at birth and 14 weeks plus IPV, and the third group receives placebo doses at birth and 14 weeks plus IPV. All groups undergo an nOPV2-002 challenge at about 18 weeks of age. The vaccine is administered at birth and at 14 weeks depending on the group, with IPV given at 6, 10, and 14 weeks. Throughout the study, stool samples are collected to measure viral load, neutralizing activity, seroprotection, seroconversion, and viral shedding up to 22 weeks of age. Safety is monitored by tracking serious and solicited adverse events. Participants are followed until 22 weeks old, with regular assessments to evaluate mucosal intestinal immunity and vaccine impact on virus transmission.
CONDITIONS
Brief Title
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Research Team
R
Ricardo Rüttimann, Dr.
G
Gabriela Aguirre
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here